Clinical Trial Search

Primary: Geometric Mean Titers of Influenza Antibodies Before and Following Vaccination With a Trivalent Inactivated Influenza Vaccine — 12.8; 24.3; 11.2; 9 Titers (1/dilution)

Primary: Linear Regression of Maximal Percent Reduction in Serum Monoclonal (M) Protein on Baseline Percent CD56^Dim Cells in Bone Marrow — -2.562; 2.464; 0.274 % chg from BL in…

Primary: Incidence of Adverse Events (TEAEs) — 5; 2; 0 participants

Primary: Toxicity — 2; 0 Events

Primary: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT Analysis) — 1.6; -62.5 percent change — p=<0.0001

Primary: Progression-free Survival — 2.6; 1.8 months

Primary: Insulin Sensitivity — 0.08; -0.11 10^-4/pmol*l/min — p=<0.01

Primary: Matched VE Participants — 26; 22; 16; 1 participants

Primary: Cmin/Cmax: Fasting Steady-state Plasma Amprenavir (APV) Pharmacokinetics (PK) Following Admin of Fosamprenavir (FPV) 1400mg BID, FPV 700mg/Ritonavir (RTV) 100 mg BID, or…

Primary: Cmin/Cmax: Steady-state Plasma Amprenavir (APV) Pharmacokinetics ( PK) Following Admin of Fosamprenavir (FPV) 1400mg BID, FPV 700mg/Ritonavir (RTV) 100 mg BID, or FPV…

Primary: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response ) — 63.6 percentage of participants

Primary: Part II: Objective Response Rate of HER2-negative Metastatic Breast Cancer (by FISH Testing) — 7 percentage of participants

Primary: Cmin/Cmax: Steady-state Plasma Amprenavir (APV) Pharmacokinetics (PK) Following Admin of Fosamprenavir (FPV) 1400mg BID, FPV 700mg/Ritonavir (RTV) 100 mg BID, or FPV…

Primary: Percentage of Participants With Major Adverse Cardiovascular Events (MACE) — 13.14; 17.12 percentage of participants — p=0.7108

Primary: Percentage of Participants With a Mean Corrected Total Serum Calcium Value < 10.2 mg/dL (2.55 mmol/L) During the Efficacy Assessment Phase (EAP) — 3.5; 78.9 percentage…